Name | Azelastine hydrochloride |
Description | Azelastine hydrochloride (Astelin) is a phthalazinone derivative with antihistaminergic activity. |
In vivo | In the rat basophilic leukemia RBL-2H3 cell line, Azelastine inhibited antigen (Ag)-induced TNF-alpha release (IC50=25.7 mM) and ionomycin-induced TNF-alpha release (IC50=1.66 mM). In mouse peritoneal macrophages, Azelastine suppressed inducible nitric oxide synthase (iNOS) mRNA expression and nitric oxide (NO) production. In normal human mast cells, Azelastine inhibited the secretion of IL-6, TNF-alpha, and IL-8, and the activation of NF-κB, as well as intracellular calcium levels. In human gingival fibroblasts, Azelastine dose-dependently inhibited DNA and protein synthesis. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 84 mg/mL (200.78 mM), Sonication is recommended. H2O : 35 mg/mL (83.66 mM), Sonication is recommended. Ethanol : 57 mg/mL (136.25 mM), Sonication is recommended.
|
Keywords | SARS-CoV | SARSCoV | SARS coronavirus | Inhibitor | inhibit | HistamineReceptor | Histamine Receptor | H1 receptor | Azelastine Hydrochloride | Azelastine hydrochloride | Azelastine | asthma | antihistamine | allergic rhinitis |
Inhibitors Related | EIDD-1931 | Meclizine dihydrochloride | Remdesivir | Silymarin | Lidocaine | Molnupiravir | Hydroxychloroquine | Famotidine | Chloroquine phosphate | Sodium butanoate | Dexamethasone | Alginic acid |
Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Cancer Drug Library |